The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic retinopathy who have previously responded to at least 2 intravitreal ...